We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BSL:ASXBluescope Steel Limited Analysis

Data as of 2026-03-14 - not real-time

A$26.25

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

BlueScope Steel is trading at AUD 26.25, just below its 20‑day SMA of 27.54 and well under the 50‑day SMA of 28.76, while still above the 200‑day SMA of 24.53, indicating a neutral technical stance. The RSI of 37 hints at mild oversold conditions, yet the MACD remains bearish with the line below the signal, and volume trends are decreasing, suggesting limited short‑term momentum. Price sits close to a calculated support of 25.69 and faces resistance near 30.10, with a quoted upside of roughly 19 % to the median analyst target of 31.14.
Fundamentally, the company posted a 4 % revenue growth and a higher first‑half profit, but its trailing PE of 46× is steep, even though the forward PE compresses to 13×. The dividend yield of 3.6 % looks attractive, yet a payout ratio above 100 % raises sustainability concerns. With a 30‑day volatility of 26 % and a beta below one, the stock is moderately volatile but less correlated with the market. Analyst consensus remains a “buy,” driven by the upside potential, improving earnings outlook, and solid balance‑sheet cash, tempered by cyclical steel sector risks and dividend sustainability questions.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 6/10

Key Factors

  • Price near support level with modest upside to resistance
  • RSI indicating slight oversold condition
  • High dividend yield offset by unsustainable payout

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Forward EPS growth driving a forward PE of 13×
  • Analyst price target implying ~19 % upside
  • Improved first‑half earnings and revenue growth

Long Term

> 3 years
Neutral
Model confidence: 7/10

Key Factors

  • Cyclical nature of the steel industry and regulatory pressures
  • Dividend sustainability concerns with payout >100 %
  • Solid cash position but high leverage (debt‑to‑equity ~9.5)

Key Metrics & Analysis

Financial Health

Revenue Growth4.00%
Profit Margin1.78%
P/E Ratio46.1
ROE3.43%
ROA3.69%
Debt/Equity9.45
P/B Ratio1.1
Op. Cash FlowA$1.6B
Free Cash FlowA$48.1M

Technical Analysis

TrendNeutral
RSI37.4
SupportA$25.69
ResistanceA$30.10
MA 20A$27.54
MA 50A$28.76
MA 200A$24.53
MACDBearish
VolumeDecreasing
Fear & Greed Index72.88

Valuation

Fair ValueA$1.77
Target PriceA$31.36
Upside/Downside19.46%
GradeFair
TypeValue
Dividend Yield3.62%

Risk Assessment

Beta0.72
Volatility26.07%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.